Litcius/Paper detail

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti, Tiziana Pressiani, Daniele Lavacchi, Jessica Lucchetti, Guido Giordano, Mario Scartozzi, Emiliano Tamburini, Alessandro Pastorino, Ilario Giovanni Rapposelli, Bruno Daniele, Erika Martinelli, Ingrid Garajová, Giuseppe Aprile, Marta Schirripa, Vincenzo Formica, Francesca Salani, Costanza Winchler, Francesca Bergamo, Rita Balsano, Eleonora Gusmaroli, A. Lorenzo, Matteo Landriscina, Andrea Pretta, I. Toma, Chiara Pirrone, Anna Diana, Francesco Leone, Oronzo Brunetti, Giovanni Brandi, Silvio Ken Garattini, Maria Antonietta Satolli, Federico Rossari, Lorenzo Fornaro, Monica Niger, Valentina Zanuso, Antonio De Rosa, Francesca Ratti, Luca Aldrighetti, Filippo de Braud, Silvia Foti, Mario Domenico Rizzato, Caterina Vivaldi, Stefano Cascinu, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei‐Gardini

2024Targeted Oncology24 citationsDOIOpen Access PDF

Topics & Concepts

GemcitabineDurvalumabMedicineCisplatinBiliary tract cancerOncologyInternal medicineBiliary tractChemotherapyCancerNivolumabImmunotherapyCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPancreatic and Hepatic Oncology Research
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study | Litcius